STING1 and neoplasm: The combination of a stimulator of an interferon gene (STING) agonist-loaded lipid nanoparticles (STING-LNP) and anti-PD-1 monotherapy synergistically enhanced anti-tumor activity through NK cell activation, while anti-PD-1 therapy alone failed to limit lung metastasis of melanoma in mice [179].